Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05448950 · ClinicalTrials.gov registry record · NA
Continued Access Study VIG Anastomotic Connector
A NA study, sponsored by Phraxis.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT05448950: Completed NA study, sponsored by Phraxis.
NCT05448950 is a NA study that has completed, run by Phraxis. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05448950, a NA study, has completed, sponsored by Phraxis.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The continued access study of the InterGraft Venous Anastomotic Connector (Venous InterGraft Continued Access Study, or 'VIG-CAS') allows for continued enrollment of subjects while the marketing application is being prepared and subsequently reviewed by FDA. The VIG-CAS will include the same patient population, follow-up schedule, and study endpoints as the VIG pivotal study.
Primary Outcome
Percentage of subjects free from loss of access of the AVG for hemodialysis
Interventions
- DEVICE VIG Continued Access Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2023-03-08 |
| Phase | NA |
What the finished NCT05448950 record still lists
NCT05448950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which VIG Continued Access Study is the first listed.
NCT05448950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05448950 about?
NCT05448950 is a clinical study titled "Continued Access Study VIG Anastomotic Connector". The continued access study of the InterGraft Venous Anastomotic Connector (Venous InterGraft Continued Access Study, or 'VIG-CAS') allows for continued enrollment of subjects while the marketing application is being prepared and subsequently reviewed by FDA. The VIG-CAS will include the same patient...
What is the current status of trial NCT05448950?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-06-07. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT05448950?
The interventions under investigation include: VIG Continued Access Study (DEVICE).
Who is sponsoring clinical trial NCT05448950?
This trial is sponsored by Phraxis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05448950's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI